January 28, 2010 / 1:17 PM / 8 years ago

UPDATE 2-Bristol beats forecast, helped by lower taxes

* EPS $0.47 shr., excl. items, vs. $0.41 forecast

* Favorable taxes drive earnings beat

* Bristol, Lilly reach deal on ImClone lung cancer drug

* Bristol, AstraZeneca file for Onglyza/metformin pill (Adds details on earnings, sales)

By Ransdell Pierson

NEW YORK, Jan 28 (Reuters) - Bristol-Myers Squibb (BMY.N) reported stronger-than-expected fourth quarter earnings, helped by sharply lower taxes and cost cuts, and forecast 2010 earnings in line with Wall Street expectations.

The company said it had settled a long-simmering dispute with Eli Lilly and Co (LLY.N), under which the rival U.S. drugmakers will co-develop a promising experimental lung-cancer drug which Lilly acquired through its purchase in late 2008 of biotechnology company ImClone Systems.

Bristol-Myers reported fourth-quarter net income of $8.03 billion, or $4.06 per share, including a $7.2 billion after-tax gain from the split-off of its Mead Johnson nutritionals business late last year. In the year-ago period, Bristol-Myers earned $1.24 billion, or 63 cents per share.

Excluding special items, Bristol-Myers earned 47 cents per share. Analysts on average expected 41 cents per share, according to Thomson Reuters I/B/E/S.

The earnings beat was largely due to a favorable tax rate, an ongoing cost-savings program and sales growth, the company said..

Global company sales from continuing operations rose 11 percent to $5.03 billion, but would have risen only 7 percent if not for the weaker dollar. Thomson Reuters expected sales of $4.99 billion, excluding Mead Johnson operations.

Sales of blood-clot preventer Plavix rose 10 percent to $1.62 billion. Bristol-Myers,, which co-markets the pill with Sanofi-Aventis (SASY.PA), is racing to cut costs and acquire new products before its top-selling product faces U.S. generic competition in 2012.

Global sales of Abilify, used to treat schizophrenia and depression, continued to spearhead company earnings growth, with sales jumping 17 percent to $707 million.

But Erbitux sales fell 8 percent to $167 million, hurt by competition from newer colon cancer treatments.

Bristol-Myers, which held a stake in ImClone and helped develop its Erbitux, has contended it also shared rights to ImClone’s lung cancer medicine — called necitumumab (IMC-11F8) — after Lilly purchased ImClone. The drug is now in late-stage trials.

Under their new agreement, Bristol-Myers and Lilly together will develop and co-market necitumumab in the U.S., Canada and Japan, should it be approved, Bristol-Myers said.

Lilly will retain rights in all other countries to the drug, which Cowen and Co has said could garner sales of $300 million in 2015.

Bristol-Myers forecast full-year earnings of $2.15 to $2.25 per share, excluding items, reflecting growth of about 16 to 22 percent. Wall Street is expecting $2.19 per share. (Reporting by Ransdell Pierson, editing by Dave Zimmerman)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below